Vaxiion Therapeutics, Inc. is a San Diego-based biotechnology company dedicated to becoming the industry leader in targeted oncology therapeutics.  The company is continuing development of a closely related pair of proprietary first-in-class nanodelivery platforms offering distinct competitive advantages for targeted delivery in cancer. Vaxiion’s targeted nanodelivery platforms are based on genetically engineered, non-living bacterial minicells that are capable of packaging, targeting, and delivering a wide array of therapeutically relevant molecules (including protein toxins, small molecule drugs, RNAi, plasmids, peptides, and imaging agents) directly to cancer cells.  The key differentiating feature of Vaxiion’s platforms versus most other targeted nanodelivery platforms or antibody-drug conjugates in development is the unique ability to promote endosomal escape, thereby resulting in better efficacy of the therapeutic payload.